Oak Thistle LLC Acquires New Position in Cencora, Inc. (NYSE:COR)

Oak Thistle LLC bought a new position in Cencora, Inc. (NYSE:COR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,023 shares of the company’s stock, valued at approximately $455,000.

Several other institutional investors also recently bought and sold shares of COR. Signal Advisors Wealth LLC grew its position in shares of Cencora by 19.5% in the fourth quarter. Signal Advisors Wealth LLC now owns 1,831 shares of the company’s stock valued at $411,000 after purchasing an additional 299 shares during the period. Ayrshire Capital Management LLC lifted its position in Cencora by 5.3% during the fourth quarter. Ayrshire Capital Management LLC now owns 25,817 shares of the company’s stock worth $5,801,000 after buying an additional 1,292 shares during the period. Wright Investors Service Inc. boosted its stake in Cencora by 253.0% in the 4th quarter. Wright Investors Service Inc. now owns 7,522 shares of the company’s stock worth $1,690,000 after buying an additional 5,391 shares during the last quarter. Unique Wealth LLC grew its holdings in Cencora by 7.1% in the 4th quarter. Unique Wealth LLC now owns 1,385 shares of the company’s stock valued at $311,000 after buying an additional 92 shares during the period. Finally, Miracle Mile Advisors LLC acquired a new position in shares of Cencora during the 4th quarter valued at about $273,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on COR shares. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Leerink Partners dropped their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a report on Monday, October 7th. Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Finally, Wells Fargo & Company dropped their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research note on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,696 shares of company stock valued at $22,862,734. Corporate insiders own 15.80% of the company’s stock.

Cencora Price Performance

COR stock opened at $240.51 on Friday. The firm has a market cap of $46.49 billion, a P/E ratio of 32.03, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The stock has a 50-day simple moving average of $237.65 and a 200-day simple moving average of $233.72.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.